| Sponsor |
Protocol Code |
Trial Name |
Principal Investigator |
Phase |
Therapeutic Area |
Diseases and Conditions |
| Taewoong Medical Co. |
TWTPV-E1001 |
PULSTA™ Transcatheter Pulmonary Valve (TPV)
Pre-approval Study |
ENDER ÖDEMİŞ (Prof.Dr.) |
Medical Device |
Cardiology |
Valvular Heart Disease |
| Novartis |
CKJX839D12302 |
A randomized, double blind, placebo conrolled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients |
DİLEK URAL (Prof.Dr.) |
Phase 3 |
Cardiology |
Cardiovascular Diseases |
| AstraZeneca |
D7960C00015 |
A Phase III, Randomised, Double-blind, Placebo-controlled,
Parallel-group Study to Assess the Effect of AZD0780 on Major
Adverse Cardiovascular Events in Patients with Established
Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk
for a First ASCVD Event |
DİLEK URAL (Prof.Dr.) |
Phase 3 |
Cardiology |
Cardiovascular Diseases |
| Anthos Therapeutics |
ANT-010 |
A Phase 3, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC) |
EROL TÜLÜMEN (Prof.Dr) |
Phase 3 |
Cardiology |
Cardiac Arrhythmias |